366 related articles for article (PubMed ID: 15591421)
1. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
2. rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H
Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
[TBL] [Abstract][Full Text] [Related]
3. rHuEPO and treatment outcomes: the clinical experience.
Hudis CA; Van Belle S; Chang J; Muenstedt K
Oncologist; 2004; 9 Suppl 5():55-69. PubMed ID: 15591423
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?
Harrison L; Blackwell K
Oncologist; 2004; 9 Suppl 5():31-40. PubMed ID: 15591420
[TBL] [Abstract][Full Text] [Related]
5. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
7. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
9. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma.
Dammacco F; Luccarelli G; Prete M; Silvestris F
Rev Clin Exp Hematol; 2002; Suppl 1():32-8. PubMed ID: 12735213
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial experience using erythropoietin during radiation therapy.
Lavey RS
Strahlenther Onkol; 1998 Dec; 174 Suppl 4():24-30. PubMed ID: 9879344
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
Pinel S; Barberi-Heyob M; Cohen-Jonathan E; Merlin JL; Delmas C; Plenat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):250-9. PubMed ID: 15093922
[TBL] [Abstract][Full Text] [Related]
13. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation.
Stüben G; Thews O; Pöttgen C; Knühmann K; Sack H; Stuschke M; Vaupel P
Strahlenther Onkol; 2003 Sep; 179(9):620-5. PubMed ID: 14628128
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
15. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
17. The erythropoietin receptor and its expression in tumor cells and other tissues.
Farrell F; Lee A
Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
[TBL] [Abstract][Full Text] [Related]
18. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
19. EPO in cancer anemia: benefits and potential risks.
Milano M; Schneider M
Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]